Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19 | Zendy

Rajiv Sonti | Zendy; C. William Pike | Zendy; Nathan Cobb | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19

Author(s) -

Rajiv Sonti,

C. William Pike,

Nathan Cobb

Publication year - 2020

Publication title -

journal of intensive care medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.866

H-Index - 58

eISSN - 1525-1489

pISSN - 0885-0666

DOI - 10.1177/0885066620976525

Subject(s) - medicine , covid-19 , respiratory failure , respiratory system , betacoronavirus , intensive care medicine , anesthesia , virology , outbreak , disease , infectious disease (medical specialty)

Inhaled pulmonary vasodilators are used as adjunctive therapies for the treatment of refractory hypoxemia. Available evidence suggest they improve oxygenation in a subset of patients without changing long-term trajectory. Given the differences in respiratory failure due to COVID-19 and "traditional" ARDS, we sought to identify their physiologic impact.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research